TrialSignal
Clinical trial intelligence report
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of Two Dose Levels of Albiglutide Compared With Placebo in Subjects With Type 2 Diabetes Mellitus
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 20, 2026
NCT ID
NCT00849017
Status
COMPLETED
Phase
Phase 3
Sponsor
GlaxoSmithKline
Executive brief
Investment-Ready Snapshot
Albiglutide, a GLP-1 receptor agonist developed by GlaxoSmithKline, aims to provide an effective treatment option for patients with Type 2 Diabetes Mellitus. The global diabetes market is projected to grow significantly, driven by increasing prevalence and demand for innovative therapies. Albiglutide's efficacy in reducing HbA1c levels positions it competitively against existing therapies, including other GLP-1 receptor agonists and insulin. The completion of this Phase 3 trial enhances GSK's portfolio and may facilitate market entry, pending regulatory approval. However, the competitive landscape remains robust, necessitating strategic positioning and potential partnerships to maximize market penetration.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT00849017
Indication
Diabetes Mellitus, Type 2
Modality
protein therapy
Target
GLP-1 receptor
Intervention
albiglutide, albiglutide uptitration, placebo
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.